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Abstract
Background: Acute pancreatitis is the most common major complication after endoscopic retrograde
cholangiopancreatography (ERCP). Many drugs have been evaluated for prophylaxis, including nonsteroidal
anti-inflammatory drugs (NSAIDs), which are potent inhibitors of phospholipase A2 and play a role in the pathogenesis of
acute pancreatitis. Rectal NSAIDs have been shown in prospective studies to decrease the incidence of this complication,
but the indication is not generalized in clinical practice. The aim of this study was to evaluate the efficacy of
rectal administration of indomethacin in reducing the incidence of post-ERCP pancreatitis in high-risk patients.
Methods: This was a controlled clinical trial where patients with an elevated risk of developing post-ERCP pancreatitis
were assigned to receive 100 mg of rectal indomethacin or a 2.6 g suppository of glycerin immediately after ERCP,
without placement of a pancreatic stent. The patients were determined to be at high risk based on validated patient- and
procedure-related risk factors. Post-ERCP pancreatitis was defined as the presence of new upper abdominal pain,
hyperamylasemia/hyperlipasemia (at least three times the upper limit) 2 hours after the procedure and hospitalization at
least 48 hours because of the complication. Pancreatitis severity was defined according to Cotton’s criteria.
Results: One hundred sixty-six patients were included; 82 in the study group and 84 in the placebo group.
Patients had at least one major and/or two minor risk factors for developing post-ERCP pancreatitis. The
incidence of the complication was 4.87 % (4/82) in the study group and 20.23 % (17/84) in the placebo
group; this difference was significant (P = 0.01). According to Cotton’s criteria, 17 patients (80.9 %) developed
mild pancreatitis and 4 (19.1 %) had moderate pancreatitis; 3 of these 4 patients belonged to the placebo
group (P = 0.60). Based on these results, an absolute risk reduction of 0.15 (15 %), a relative risk reduction of
0.75 (75 %) and a number needed to treat of 6.5 patients were calculated to prevent an episode of
post-ERCP pancreatitis. There was no mortality.
Conclusions: Rectal indomethacin reduced the incidence of post-ERCP pancreatitis among patients at high
risk of developing this complication.
Trial registration: National Clinical Trials NCT02110810. Date April 7, 2014.
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Background
Endoscopic retrograde cholangiopancreatography (ERCP)
is now widely accepted as a therapeutic modality of be-
nign and malignant diseases of the pancreatobiliary tree.
Acute pancreatitis represents the most common and
feared complication following ERCP. The reported inci-
dence of this complication is 1–40 % according to the
presence of high-risk factors or the presence of sphincter
of Oddi dysfunction (SOD) [1]. In most of the prospective
series, the incidence reported ranged between 3.5 % and
20 % for nonselected and for high-risk patients, respect-
ively. Independent risk factors for post-ERCP pancreatitis
(PEP) are either patient- or procedure-related [1, 2].
Although most episodes of PEP are mild (80–90 %), a
small proportion of patients develop severe pancreatitis,
resulting in prolonged hospitalization, a long stay in the
Intensive Care Unit and utilization of major hospital re-
sources. These patients have increased morbidity and
mortality rates [3]. Despite technical improvements and
increased skills for endoscopists, the incidence of PEP
has not yet decreased substantially [4].
To date, pancreatic stent placement appears to be the
best way to reduce the incidence of this complication in
high-risk patients; it is currently recommended by some
guidelines [5, 6] and is considered the standard of care
for the prevention of PEP [7].
However, pancreatic stenting is a difficult maneuver
to perform and comes relatively late (at the end of
the endoscopic procedure), mainly in patients with
difficult cannulation of the biliary–pancreatic ducts;
in addition, many endoscopists are not familiar with
this procedure. This unique maneuver may leave the
patient worse off than if no attempt was made to per-
form the procedure [8].
There is no gold standard to prevent this complica-
tion. For this reason, more than 35 pharmacologic
agents have been studied in many prospective clinical
trials. To date, no medication has proven to be consist-
ently effective in preventing PEP and no pharmaco-
logical prophylaxis is in widespread clinical use [9–12].
Nonsteroidal anti-inflammatory drugs (NSAIDs) are
potent inhibitors of phospholipase A2, cyclooxygenase
and neutrophil–endothelial interactions, all believed to
play an important role in the pathogenesis of acute pan-
creatitis. NSAIDs are inexpensive and easily adminis-
tered and have a favorable risk profile when given as a
single dose, making them an attractive option in the pre-
vention of PEP. Preliminary studies evaluating the pro-
tective effects of single-dose rectal indomethacin or
diclofenac in PEP have been conducted, and meta-
analyses suggest a benefit [12, 13].
Prophylaxis of PEP constitutes a continuous challenge.
The ideal prophylactic agent should be a drug with a
low cost, be easily administrated and with mild or no
adverse effects. The identification of patients at a high
risk of this complication is difficult before the endo-
scopic procedure because many risk factors are
procedure-related. There is some evidence to suggest a
beneficial effect from the use of NSAIDs applied rectally
immediately after the conclusion of ERCP [14–16].
The aim of this study was to evaluate the efficacy of
rectally administered indomethacin in reducing the inci-
dence of PEP in high-risk patients.
Methods
Design
This was a controlled clinical trial conducted between
July 2012 and December 2013 in patients scheduled for
ERCP at the Department of Gastrointestinal Endoscopy
and Department of Gastroenterology of the Specialties
Hospital of the Western Medical Center in Guadalajara,
Jalisco, Mexico.
The inclusion criteria selected patients with an ele-
vated baseline risk of PEP on the basis of prospectively
validated patient- and procedure-related independent
risk factors [17, 18].
Patients were eligible if they met one or more of the
following criteria: clinical suspicion of SOD, a history of
PEP, pancreatic sphincterotomy, precut sphincterectomy,
more than eight cannulation attempts, pneumatic dilata-
tion of an intact biliary sphincter, or ampullectomy. In
addition, they were also eligible for inclusion if they met
at least two of the following criteria: age less than
50 years and female sex, a history of recurrent pancrea-
titis (> two episodes), three or more injections of con-
trast agent into the pancreatic duct with at least one
injection to the tail of the pancreas, excessive injection
of a contrast agent into the pancreatic duct resulting in
opacification of pancreatic acini, or the acquisition of a
cytologic specimen from the pancreatic duct with the
use of a brush.
The exclusion criteria were: unwillingness or inability
to consent to the study, age less than 18 years, preg-
nancy, breastfeeding mother, standard contraindication
for ERCP, hypersensitivity to aspirin or NSAIDs, previ-
ous use of NSAIDs within 1 week, creatinine level ≥
1.6 mg/dl, active or recent (4 weeks) gastrointestinal
hemorrhage, chronic calcified pancreatitis, pancreatic
head malignancy, procedure performed on major papilla/
ventral pancreatic duct in a patient with pancreas divisum,
ERCP for biliary stent removal or exchange without antici-
pated pancreatogram, subjects with prior biliary sphincter-
otomy now scheduled for repeat biliary therapy without
anticipated pancreatogram and anticipated inability to
follow the study protocol.
The ERCP procedures were performed with the pa-
tient under topical pharyngeal anesthesia with 2 % lido-
caine and after administration of sedation (midazolam)
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and analgesia (fentanyl) intravenously, with dosage at
the discretion of the endoscopist. Patients received com-
plementary oxygen (3 to 5 l/min) through a nasal exter-
nal device and infusion of 200 to 500 ml of 0.9 % saline
solution. The material used to perform ERCP consisted
of a video duodenoscope model TJF-Q180V (Olympus™),
traction sphincterotome for selective cannulation of the
bile duct, needle scalpel to perform the precut sphincter-
otomy, hydrophilic guide wire via the bile duct, Dormia
basket and/or balloon catheter for stone extraction, and
nonionic water-soluble contrast in concentration of
300 mg I/ml (Optiray™ 300) for opacification of the bil-
iary and pancreatic ducts. Pancreatic stents were only
used to treat pancreatic fistulas, not to prevent any pan-
creatitis events in any cases. All patients were monitored
continuously during the procedure, with measurements
of blood pressure, heart rate, respiratory rate and arterial
oxygen saturation.
Eligible patients provided written informed consent be-
fore ERCP and underwent randomization at the conclusion
of the endoscopic procedure. Patients without risk factors
were not included in the study, based on procedure-related
factors alone. If patients met the inclusion criteria, they
were randomly assigned to receive a 100 mg suppository of
indomethacin or a 2.4 g glycerin suppository of identical
appearance after ERCP while patients were under the effect
of sedative medication. All patients were kept under sur-
veillance until they became completely awake to prevent
spontaneous expulsion of the suppository. The patients,
staff endoscopists, residents and researchers were blinded
to the treatment assigned to each participant.
The following information was collected. 1) Clinical his-
tory, particularly patient-related risk factors for PEP, blood
exams for determination of basal amylase, liver enzymes
and bilirubin levels, as well as results of ultrasound exam-
ination of the liver and biliary tract. 2) All information
generated during the ERCP was recorded, particularly pa-
rameters related to the procedure risk factors for develop-
ing acute pancreatitis. In addition, other nonpancreatic
complications were recorded, such as perforation and
bleeding. 3) Adverse events related to the rectally applied
indomethacin or glycerin suppositories were recorded,
such as expulsion, irritation and bleeding.
PEP was considered the main outcome variable and
was defined as the development of new or increased
abdominal pain consistent with pancreatitis, and ele-
vated amylase or lipase greater than three times the
normal upper limit until 24 hours after the proced-
ure, and hospitalization (or prolongation of existing
hospitalization) for at least 2 nights. The severity was
determined according to consensus guidelines, with mild
PEP resulting in a hospitalization of < 3 days, moderate
PEP resulting in a hospitalization of 4–10 days, and severe
PEP resulting in a hospitalization of > 10 days or leading
to the development of pancreatic necrosis or pseudocyst,
or requiring percutaneous or surgical intervention. Pa-
tients who presented acute pancreatitis after CPRE pro-
cedure, were followed up for 30 days after hospital
discharge. Asymptomatic hyperamylasemia was defined as
any amylase level at least three times above the normal
serum level in the absence of abdominal pain, as defined
by the consensus criteria [19].
Follow-up
Patients were kept under surveillance in the endoscopy re-
covery area for 3 hours after ERCP. Measurement of serum
amylase was performed at 2 hours after ERCP in all study
patients. Outpatients who were asymptomatic after 4 to
6 hours of surveillance were discharged to home with mon-
itoring for signs and symptoms of acute PEP by phone for
24 hours. Hospitalized patients who were asymptomatic
after 4 to 6 hours of surveillance remained in their assigned
bed where clinical surveillance was continued for up to
24 hours. If new abdominal pain suggestive of pancreatic
origin appeared at any moment during the surveillance
period, the 2-hour amylase level was noted and confirmed
with serum lipase determination in the following hours. In
addition, all usual laboratory exams were performed when
acute pancreatitis of any etiology was established. All pa-
tients diagnosed with PEP were managed under the medical
care of the Department of Gastroenterology.
Sample size
We evaluated if the application of rectal indomethacin
had better results than placebo for the prophylaxis of
PEP, with a known incidence of PEP of 25 % in high-risk
patients and about 7.5 % in the study group [1, 2]. By
calculating the sample size for the comparison of pro-
portions with desired errors α of 0.05 and β of 0.20, a
minimum sample size of 80 patients per group was
obtained.
Statistical analysis
The descriptive phase of the analysis included the presen-
tations of data as raw values, percentages and mean ±
standard deviation. In the inference phase, Student’s t test
was used for continuous variables, and χ2 or Fisher’s exact
tests were used for qualitative variables when appropriate.
Furthermore, the absolute risk reduction (ARR), relative
risk reduction (RRR) and number needed to treat (NNT)
were calculated. Results were considered significant when
P < 0.05. Statistical analysis was conducted using Excel®
2007 (Microsoft®, Redmond, WA, USA) and SPSS® version
17 for Windows (SPSS Inc., Chicago, IL, USA).
Ethical considerations
The local Ethics Committee approved the study protocol
(identification number 2010-1301-14). All patients gave
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written informed consent and were randomized using the
technique of random numbers in sealed envelopes. The
project was carried out with the financial resources of each
department and unit, and the authors declare no conflict of
financial interest. In addition, the protocol was registered at
ClinicalTrials.gov (Identifier NCT02110810).
Results
During the study period, 166 consecutive patients who met
the inclusion and exclusion criteria were included, as
shown in Fig. 1. Eighty-two patients (49.4 %) received
100 mg indomethacin rectally (study group), and 84 pa-
tients (50.6 %) received a 2.6 g glycerin suppository (control
group). The complete cohort consisted of 110 females
(66.2 %) and 56 males (33.8 %). There were 51 females and
31 males (62.1 % and 37.8 %, respectively) in the study
group and 59 females and 25 males (70.2 % and 29.7 %, re-
spectively) in the control group. The mean age of patients
was 51.6 ± 18.5 years in the study group and 54.0 ±
17.8 years in the control group. The most frequent diagno-
sis was choledocholithiasis, observed in 34 cases (41.46 %)
in the study group and 32 patients (38.1 %) in the control
group, followed by benign biliary tract stenosis, suspected
SOD and malignant stenosis of the biliary tract. Table 1
summarizes the baseline characteristics of both groups. No
significant differences were found when variables were
compared.
Twenty-one patients developed PEP, 4 in the treatment
group (4.87 %) and 17 in the control group (20.23 %);
this difference was significant (P = 0.01). Seventeen
(80.9 %) cases of pancreatitis occurred in females and 4
cases (20.2 %) in males (P = 0.14). Based on these results,
an ARR of 0.15 (15 %), an RRR of 0.75 (75 %) and an
NNT of 6.5 patients were calculated to prevent an epi-
sode of PEP. According to Cotton’s classification, the
PEP was mild in 17 patients (80.9 %) and moderate in 4
patients (19.1 %); of these, there were 3 cases in the con-
trol group and 1 case in the treatment group (P = 0.60),
as shown in Fig. 2.
The mean age of the 21 patients with PEP was 48.3 ±
16.2 years, lower than the mean age of 53.6 ± 18.4 years
for the 145 patients without pancreatitis; however, the
difference was not significant (P = 0.21).
The length of hospital stay for those patients who suf-
fered mild pancreatitis was 2.7 ± 0.95 days and 3.8 ±
1.3 days for moderate pancreatitis (P = 0.14). There was
no mortality as a result of PEP.
Table 2 shows the diagnoses of the patients with pan-
creatitis; these were distributed similarly between the
groups (P = 0.35). At 2 hours after ERCP, the mean
Fig. 1 Distribution of patients included in the study
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serum amylase was 141.9 ± 92.6 U/l in the study group
and 216.5 ± 105.2 U/l in the control group (P < 0.001). In
patients who developed pancreatitis, the mean serum
amylase at 2 hours after ERCP was 1187.6 ± 789.3 U/l
and a mean serum lipase level of 5052.6 ± 2805.1 U/l
was measured in the first 24 hours after ERCP. Asymp-
tomatic hyperamylasemia occurred in 100 patients
(60.6 %), corresponding to 19 patients in the study group
and 81 in the control group (P < 0.001).
Risk factors for PEP are described in Table 3. They
were distributed similarly in both groups with no sig-
nificant differences. In addition, no differences in the
distribution of sex or age were observed. No significant
differences were observed when analyzing the develop-
ment of complications in patients older and younger
than 50 years (P = 0.44). However, the patients who de-
veloped pancreatitis were younger (48.3 ± 16.2 versus
53.7 ± 18.3; P = 0.21). There was no difference in the dis-
tribution of inpatients and outpatients (P = 0.51) or a
history of previous cholecystectomy (P = 0.12). However,
we observed significant differences in several outcome
results such as the number of attempts to cannulate the
bile duct, in the performance of precut sphincterotomy,
the time to cannulate the bile duct and the total dur-
ation of the procedure (P = 0.001), as well as if patients
required pancreatography, also in the number of attempts
to pass guide wires and in the injection of contrast mater-
ial into the pancreatic duct. There was no difference in
the extension of pancreatography (P = 0.39). Two patients
in each group required pancreatic stenting because pan-
creatic fistulas were diagnosed during ERCP (P = 0.62).
Other complications included minor bleeding in 2 pa-
tients of the study group and 3 patients in the control
group (P = 0.99). None of these patients required surgi-
cal treatment to resolve the complication. No perfora-
tions were observed. The only side effect observed was
itching in the anus in 2 patients in each group. There
was no mortality. The comparison between groups that
developed and did not develop PEP is described in
Table 4.
Discussion
ERCP has become an essential therapeutic modality
for pancreatic and biliary diseases since the introduc-
tion of endoscopic sphincterotomy [20]. Acute pan-
creatitis remains the most common complication of
ERCP. Other complications such as hemorrhage, per-
foration, cholangitis and cholecystitis are observed
with a lower incidence; however, these complications
are no less important because they can lead to signifi-
cant morbidity and mortality [17–19, 21].
The overall incidence of PEP in our study was 12.6 %,
which is comparable to that reported in other series,
considering that high-risk patients were studied. The fre-
quency of PEP was higher in females (17 females versus
4 males), a finding that is also consistent with those of
other prospective studies [14–18].
Our results showed that the use of indomethacin ad-
ministered rectally compared with glycerin decreased the
incidence of PEP in patients at a high risk of developing
this complication (4.87 % versus 20.23 %), a difference that
was significant (P = 0.01). The clinical and statistical sig-
nificance of the intervention was expressed by an ARR of
Table 1 Baseline characteristics of patients in the treatment and
control groups
Characteristics Indomethacin
group (N = 82)
Glycerin









Age (years) 51.59 ± 18.55 54.0 ± 17.85 0.394
Outpatients 46 45 0.74
Hospitalized 36 39
Without comorbidity 56 54 0.427
Comorbid conditions 26 30





Hepatic cirrhosisa 1 2









Previous cholecystectomy 42 40 0.643

















Pancreatic fistula 2 3
Pre-ERCP amylase level (U/L) 57.39 ± 21.56 55.36 ± 20.77 0.540
aEtiology in the indomethacin group: chronic hepatitis due to hepatitis C virus
in 1 patient. Glycerin group etiologies in chronic hepatitis due to hepatitis C
virus in 1 patient and primary biliary cirrhosis in 1 patient.
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0.15 (15 %), RRR of 0.75 (75 %) and a NNT of 6.5 patients
to prevent one episode of pancreatitis.
Since 2003, 11 studies have been published regarding
the preventive effect of NSAIDs in patients undergoing
ERCP (Table 5). Murray et al. published the first random-
ized clinical trial [14]. They compared the use of 100 mg
of rectally administered diclofenac versus placebo in the
recovery area after ERCP, including 110 patients in each
group. Risk factors for pancreatitis included as variables
were pancreatography and SOD. The incidence of pan-
creatitis in the placebo group was 15.5 % (17/110) and
6.4 % (7/110) in the diclofenac group (P = 0.049).
In 2007, Sotoudehmanesh et al. compared the use of
100 mg of rectal indomethacin with placebo, adminis-
tered immediately before the ERCP. They enrolled a het-
erogeneous group of 442 patients without distinguishing
the presence of any high-risk group. The incidence of
PEP in the placebo group was 6.8 % (15/221) and 3.2 %
(7/221) in the indomethacin group, although this dif-
ference was not significant (P = 0.06). A post hoc sub-
group analysis of patients undergoing pancreatography
showed a significant protective effect of indomethacin
(indomethacin 2.3 % versus placebo 18.6 %; P = 0.014) [15].
Moreover, in 2007, Khoshbaten et al. compared the
use of 100 mg of rectally administered diclofenac com-
pared with placebo, applied in the recovery area. They
only included patients considered to be at high risk of
PEP (patients undergoing pancreatography with or with-
out cholangiogram). The incidence of PEP in the placebo
group was 26 % (13/50) and 4 % (2/50) in the diclofenac
group; this difference was significant (P ≤ 0.01) [22].
Montaño et al. conducted a study that involved 150
patients, comparing 100 mg of rectally administered
indomethacin with placebo, applied before the proced-
ure. In this study, patients undergoing ERCP for sus-
pected biliary obstruction were included (they were not
considered at high risk of PEP). They found an incidence
of pancreatitis in the placebo group of 16 % (12/75) and
5.3 % (4/75) in the indomethacin group; this difference
was significant (P = 0.034). All cases of pancreatitis were
categorized as mild according to the consensus criteria,
as occurred in our series [23].
In 2007, Cheon et al. published the results of a clinical
trial in the USA, including patients at high (179/207)
and low (28/207) risk of developing PEP. They compared
the administration of 50 mg of oral diclofenac against
placebo, applied 30 to 90 minutes before and 4 to
6 hours after ERCP. The incidence of pancreatitis in
high-risk patients in the placebo group was 18 % (16/89)
and 17.8 % (16/90) in the diclofenac group. The differ-
ence in the incidence and severity of pancreatitis be-
tween the two treatment groups was not significant [24].
More recently, Senol et al. assessed 80 patients and
compared the administration of 75 mg of intramuscular
diclofenac followed by infusion of 0.9 % NaCl for 4 hours
(5–10 ml/kg) versus placebo (infusion of 500 cc of 0.9 %
NaCl for 4 hours). The intervention was performed im-
mediately after ERCP. The incidence of pancreatitis in
Fig. 2 Incidence and distribution of mild and moderate PEP between groups

















Severity of the episodes
of Pancreatitis
Mild 3 14 0.60
Moderate 1 3
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the placebo group was 17.5 % (7/40) and 7.5 % (3/40) in
the diclofenac group. This difference was not significant
(P = 0.176), which may have been because of the small
number of patients included [25].
In the same context, Otsuka et al. compared the ad-
ministration of 50 mg transrectal diclofenac against pla-
cebo (glycerin suppository) in 104 patients, applied
30 minutes before ERCP. They reported an incidence of
pancreatitis of 3.9 % (2/51) for the diclofenac group and
18.9 % (10/53) in the control group (P = 0.017) [26].
Elmunzer et al. conducted the most important con-
trolled clinical trial, in which they enrolled 602 patients
and compared 100 mg transrectal indomethacin against
placebo (glycerin suppository) [15]. The intervention
was performed immediately after ERCP. The incidence
of pancreatitis in the placebo group was 16.9 % (52/307)
and 9.2 % (27/295) in the indomethacin group, which
was a significant difference (P = 0.03). It should be noted
that in this study the authors placed a pancreatic stent
in 246 patients in the indomethacin group (83.4 %) and
250 individuals in the placebo group (81.4 %). In
addition, it should be highlighted that most of the pa-
tients were evaluated by clinical suspicion of SOD and
over 15 % of cases and controls had a history of PEP.
Döbrönte et al. conducted a clinical trial that included
228 patients and evaluated the rectal application of
100 mg indomethacin against placebo (glycerin supposi-
tory), administered 10 minutes before performing ERCP.
The incidence of pancreatitis in the indomethacin group
was 8.4 % (11/130) and 11.2 % (11/98) for the control
group, showing no significant difference (P = 0.48) [27].
This controlled clinical trial had an imbalance in the
number of controls with a difference of 32 patients at
the time of publishing, so the authors’ conclusions are
poorly supported.
Abu-Safieh et al. conducted a randomized double-
blind controlled trial in Palestine, including a total of
182 patients and comparing the intramuscular adminis-
tration of 75 mg diclofenac with 3 ml of isotonic saline
as a placebo. They reported an overall incidence of PEP
of 10 %, 6.9 (6/89) for the diclofenac group and 12.9 %
(12/93) for the placebo group. There was no significance
difference in the incidence of PEP between the two
groups (P = 0.164) [28].
Döbrönte et al. recently published the results of a mul-
ticenter clinical trial in 665 standard-risk patients di-
vided into 347 study patients that received 100 mg of
indomethacin before ERCP and 318 controls that re-
ceived a placebo. The incidence of PEP was 5.8 % and
6.9 % (P = 0.54) [29]. As in their previous study [27],
there was an imbalance in the number of controls with a
difference of 29 patients at the time of publishing, so the
authors’ conclusions may be insufficiently supported be-
cause of this difference.
From 2008 to the present, at least 10 meta-analyses
have evaluated the results of the different clinical trials
that have been reported. The results allow us to conclude
that NSAIDs such as indomethacin or diclofenac used in
the different routes of administration reduce the incidence
of asymptomatic hyperamylasemia, pancreatitis and mod-
erate to severe episodes of pancreatitis [12, 13, 30–37].
The results of our study are relevant because the drug
was administrated immediately after completion of the
endoscopic procedure, as was performed by Murray
[14], Khoshbaten [22] and Elmunzer [16]. Only the study
reported by Elmunzer used indomethacin; in the other
two studies, diclofenac was preferred. The main differ-
ence between our study and that reported by Elmunzer
Table 3 Patient- and procedure-related risk factors identified for
the development of PEP






Oddi - Female sex 51 59 0.27
Oddi - Suspected sphincter
dysfunction oddi
12 15 0.72






- Normal serum bilirubin. 26 24 0.66
Procedure-related
- Attempts to cannulation 7.3 ± 3.6 7.2 ± 3.5 0.97
- Time cannulation 6.0 ± 3.5 6.8 ± 3.6 0.14
- Difficult cannulation of the
bile duct (>8 attempts)
38 40 0.86






- Biliary sphincterotomy 49 48 0.73
- Diameter of the bile duct 11.5 ± 5.3 11.6 ± 4.2 0.84
- Biliary Stent 26 22 0.08
- Pancreatography 41 38 0.34
- Number of passes 1.4 ± 0.5 1.5 ± 0.8 0.25
- Number of injections 1.5 ± 0.8 1.6 ± 0.5 0.52
- Pancreatography extension
* Partial 8 6 0.14
* Full 31 30
* Acinarizacion 2 2
- Pancreatic sphincterotomy 7 5 0.36
- Brushed wirsung duct 8 9 0.33
- Pancreatic stenting 2 2 0.62
- Total procedure time 23.2 ± 6.7 24.6 ± 7.3 0.22
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was the combined use of pancreatic stenting in more
than 80 % of patients in the latter. In our study, pancre-
atic stenting was only used to treat pancreatic fistulas.
Traditionally, it has been considered that the place-
ment of a small caliber (5 Fr) stent in the pancreatic
duct was the standard treatment to prevent this compli-
cation. It has also been recommended in the manage-
ment guidelines for the prevention of pancreatitis in
patients considered to be at high risk [5–7]. Recently,
Akbar and colleagues published the results of a meta-
analysis in which a total of 29 studies were included (22
with pancreatic stent placement and 7 with the use of
NSAIDs), showing that stenting or transrectal admin-
istration of NSAIDs was superior to placebo in the
prevention of PEP. The combination of transrectal ap-
plication of NSAIDs and the use of stents showed no
Table 4 Comparison between groups with and without PEP
Characteristics Patients with post-ERCP
pancreatitis (N = 21 )
Patients without post-ERCP
pancreatitis (N = 145)
P
Female 17 93 0.14
Male 4 52
Age (years) 48.3 ± 16.2 53.7 ± 18.3 0.21
<50 years 11 63 0.44
>50 years 10 82
Ambulatory ERCP 10 81 0.51
Hospitalized ERCP 11 64
Dilated bile duct by imaging studies pre-ERCP 14 104 0.58
Without dilation bile duct by imaging studies pre-ERCP 7 41
Diameter of the bile duct by ERCP (mm) 9.0 ± 2.1 11.9 ± 5.0 0.001
With previous cholecystectomy 13 69 0.12
Without previous cholecystectomy 8 76
Elevated pre-ERCP bilirubin 18 99 0.12
Normal pre-ERCP bilirubin 3 46
Number of attempts to cannulate the biliary tract 9.1 ± 2.7 7.1 ± 3.5 0.02
Difficult cannulation
<8 attempts 5 83 0.005
>8 attempts 16 62
Precut (access) sphincterotomy
Yes 17 78 0.01
No 4 67
Biliary sphincterotomy
Yes 11 86 0.54
No 10 59
Cannulation time of the bile duct (min) 8.7 ± 2.8 6.1 ± 3.5 0.001
ERCP Length (min) 30.0 ± 3.7 23.7 ± 7.2 0.001
Pancreatography
Yes 17 62 0.002
No 4 83
Number of passes of the guide in the Wirsung duct. 2.3 ± 0.76 1.40 ± 0.75 0.000
Number of injections into the Wirsung duct. 2.0 ± 0.72 1.43 ± 0.64 0.001
Pancreatography extension
Partial 2 9 0.39
Full 13 52
Acinarization 2 1
Serum amylase at 2 hours post-ERCP (U/L) 1163.5 ± 999.6 176.9 ± 105.2 0.001
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greater effectiveness in the prevention of PEP when
compared with that of each intervention alone. The re-
sults further demonstrated that transrectally administered
NSAIDs alone were superior to pancreatic stenting in pre-
venting PEP (OR 0.48, 95 % CI, 0.26 to 0.87) and must be
regarded as the first-line preventive therapy [32].
Recently, the United States Cooperative for Outcomes
Research in Endoscopy group [38] published a post hoc
analysis of the randomized controlled trial published by
Elmunzer and colleagues [16]. They found that the inci-
dence of PEP in placebo patients who received a failed
pancreatic stent (FPS) was 34.7 %, and in those patients
in this group with a successful pancreatic stent (PS), the
incidence was 16.2 % and in patients without a PS it was
only 12.1 %. In contrast, in patients who received a sup-
pository of 100 mg of indomethacin immediately after
the ERCP, the incidence of PEP was 5.3 % in the FPS pa-
tients, 9.6 % in patients with a successful PS and 10.3 %
in those patients without a PS. This study reveals the
important and relevant results of prophylactic use of
rectal NSAIDs.
However, to support the previous conclusion, a high-
quality multicenter randomized clinical trial is required
to better understand the efficacy of pancreatic stents
with and without rectal NSAIDs and with rectal NSAIDs
alone to prevent PEP in high-risk patients.
Another important issue to consider is the cost of
prophylactic treatments. In the hospital where this study
was conducted, the cost of a suppository of 100 mg of
indomethacin was USD $0.08, the glycerin suppository
had a cost of USD $0.20 and the pancreatic endoproth-
esis had a cost of USD $350.00.
Conclusions
This study showed that indomethacin administered rec-
tally immediately after ERCP reduced the incidence of
PEP in high-risk patients.
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Post-ERCP pancreatitis incidence Risk Ratio,
95 % CIExperimental Control
Events n Events n




Yes 7 110 17 110 0.56 [0.29, 1.05]
Sotoudenhmanesh,
2007, India. [15]
100 mg rectal Indomethacin
immediately prior to ERCP.
Unselected
patients
No 7 221 15 221 0.62 [0.34, 1.16]
Montaño-Loza,
2007, Mexico. [23]
100 mg rectal Indomethacin,
2 h before ERCP.
Unselected
patients
No 4 75 12 75 0.47 [0.20, 1.12]
Cheon, 2007,
USA. [24]
50 mg Diclofenac, before
and after ERCP by mouth
Unselected
patients
Yes 17 105 17 102 0.98 [0.68, 1.42]
Khoshbaten,
2008, Iran. [22]
100 mg rectal Diclofenac
on arrival to recovery area.
High risk
patients
Yes 2 50 13 50 0.24 [0.06, 0.87]
Senol, 2009,
Turkey. [25]
75 mg diclofenac IM and
IV isotonic, after ERCP
Unselected
patients
No 3 40 7 40 0.57 [0.21, 1.50]
Otsuka, 2012,
Japan. [26]
50 mg rectal Diclofenac,
30 min before ERCP.
Unselected
patients
No 2 51 10 53 0.31 [0.09, 1.12]
Elmunzer, 2012,
USA. [16]




Yes 27 295 52 307 0.67 [0.49, 0.92]
Döbrönte, 2012,
Hungary. [27]
100 mg rectal Indomethacin,
10 min before ERCP.
Unselected
patients
No 11 130 11 98 0.87 [0.56, 1.34]
Abu-Safieh Yasser,
2014, Palestine. [28]




Yes 6 89 12 93 0.66 [0.34, 1.29]
Döbrönte, 2014,
Hungary. [29]
100 mg rectal Indomethacin
10–15 min before ERCP.
Unselected
patients
No 20 347 22 318 1.10 [0.82, 1.49]
Present Study,
2015, México.




No 4 82 17 84 0.35 [0.14, 0.87]
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